Using lipid nanoparticles (LNPs), engineers have successfully delivered genetic material to the lung that suppresses lung tumors in mice.
Quantum traffic laws applied to the 3D streetscape of a specific kind of crystal can put the brakes on electron rush hour.
In a search for novel materials that can contain bizarre new states of matter, physicists from Rice University in the US led an experiment that forced free-roaming electrons to stay in place.
While the phenomenon has been seen in materials where electrons are constrained to just two dimensions, this is the first time it’s been observed in a three-dimensional crystal metal lattice, known as a pyrochlore. The technique gives researchers a new tool for studying the less conventional activities of plucky, charge-carrying particles.
Cancer survivor, Gail Baron Simpson, shares her personal journey to treatment success in this in-depth interview with Precision Oncology specialist and CTOAM co-founder, Alex Rolland, and Michelle Morand, Precision Cancer Medicine Advocacy specialist and CTOAM co-founder.
Please watch our short intro video to Gail’s story first! 👉 • Introduction to Gail’s Incredible Can…
Join us for an extraordinary livestream webinar, ‘Paving the Way for the Future: Learning from 4 Biostasis Cases and the Challenges and Advancements at Tomorrow Bio’ featuring esteemed speakers Dr. Emil Kendziorra and Dr. Irishikesh Santhosh from Tomorrow Biostasis GmbH. This pivotal session, scheduled for March 18th, 2024, at 7:00 PM, will delve into the latest advancements and real-world applications of biostasis, focusing on the detailed processes and outcomes associated with four distinct patient cases from 2023.
In this webinar, we will explore the intricate procedures and challenges encountered during the biostasis process, including stabilization in the face of cardiopulmonary arrest, the nuances of surgical and perfusion procedures, and the critical cooldown process for long-term storage. Our experts will unpack the innovative techniques employed, the utilization of cryoprotectant solutions, cooling techniques, and the diligent monitoring through CT scans, alongside the resolution of unforeseen technical challenges.
Continue reading “Biostasis Progress: Unveiling 4 Patient Cases from Tomorrow Bio” »
A computational model of the more than 26 million atoms in a DNA-packed viral capsid expands our understanding of virus structure and DNA dynamics, insights that could provide new research avenues and drug targets, University of Illinois Urbana-Champaign researchers report in the journal Nature.
“To fight a virus, we want to know everything there is to know about it. We know what’s inside in terms of components, but we don’t know how they’re arranged,” said study leader Aleksei Aksimentiev, an Illinois professor of physics. “Knowledge of the internal structures gives us more targets for drugs, which tend to focus on receptors on the surface or replication proteins.”
3D processors for wireless communications? Now great and discovered by DARPA!
A breakthrough in the creation of 3D processors using semiconductor technology could reshape the future of wireless communication.
A group of researchers created a first-generation AI worm that can steal data, spread malware, and spam others via an email client to spread through multiple systems.
Researchers successfully tested this Morris II worm and published its findings using two methods.
The first UK patients received the experimental mRNA therapy – a type of immunotherapy treatment called mRNA-4359 – at Imperial College Healthcare NHS Trust as part of a phase 1/2 clinical trial. The trial aims to evaluate its safety and potential for treating melanoma, lung cancer and other ‘solid tumour’ cancers.
The treatment is designed using messenger RNA (mRNA) and works by presenting common markers of tumours to the patient’s immune system. This should help to train patients’ immune systems to recognise and fight cancer cells expressing these markers, but also potentially eliminate cells that may suppress the immune response.
The University of Chicago Medicine is among the first 30 institutions in the country to offer tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, immediately activating as an authorized treatment center after federal regulators approved the treatment on February 16, 2024.
TILs are…
Some patients with advanced melanomas — those that can’t be surgically removed or have spread to other parts of the body — don’t respond to standard treatment options such as immunotherapies and targeted therapies. TIL therapy gives these patients another therapeutic option: a completely personalized treatment made from the patient’s own cells that needs to be administered only once, since the cells remain in the body and keep performing their tumor-attacking duties.
Continue reading “UChicago Medicine to offer TIL therapy for advanced melanoma” »
